Gamma-aminobutyric acid type A receptor subunit alpha 2 (GABRA2) (GABRA2)

The gamma-aminobutyric acid type A (GABAA) receptor subunit alpha 2 is a critical component of the heteropentameric GABAA receptor complex, which serves as the primary inhibitory neurotransmitter-gated ion channel in the mammalian central nervous system (UniProt: P47869). These receptors are ligand-gated chloride channels that mediate fast inhibitory synaptic transmission; the alpha 2 subunit specifically dictates the receptor's localization and unique pharmacological properties (PubMed: 21606927). Alpha 2-containing GABAA receptors are predominantly expressed in the limbic system, including the amygdala and hippocampus, as well as on the axon initial segments of pyramidal neurons, where they regulate neuronal excitability and emotional processing (PubMed: 11024670). Pharmacologically, these receptors are the primary mediators of the anxiolytic and analgesic effects of benzodiazepines, distinguishing them from alpha 1-containing receptors which primarily mediate sedation and amnesia (StatPearls: Benzodiazepines). Consequently, the alpha 2 subunit is a high-priority therapeutic target for developing selective positive allosteric modulators (PAMs) intended to treat generalized anxiety disorder, epilepsy, and chronic pain without the sedative side effects or abuse liability associated with non-selective agents (PubMed: 15148132).

Other names

GABAA receptor alpha 2 subunitGABRA2Alpha-2 GABA-A receptorGABA(A) receptor subunit alpha-2GABA(A) receptor alpha-2

Positive allosteric modulation of the GABAA receptor at the benzodiazepine binding site (alpha/gamma interface), which enhances the inhibitory effect of GABA by increasing chloride ion conductance (PubMed: 21606927).